214 results about "Elevated creatinine" patented technology

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

The invention belongs to the field of biological medicines, and particularly discloses application of a Ptprj agonist GJ103 in preparation of a medicine for treating acute kidney injury (AKI) induced by cisplatin. In-vivo and in-vitro experiments prove that the GJ103, by activating Ptprj, can significantly down-regulate expression of pro-apoptotic protein Bax and Cleved Caspase-3, up-regulate anti-apoptotic protein Bcl2 and reduce infiltration of inflammatory factors TNF-alpha and IL-6, so that apoptosis and inflammatory response of renal tubular epithelial cells are relieved. In in-vivo experiments, GJ103 (20-40mg / kg / day) can reduce serum creatinine and urea nitrogen levels of cis-platinum model mice and improve pathological injuries such as renal tubule dilatation; in in-vitro experiments, 20-40 [mu] M of GJ103 can inhibit apoptosis of renal tubular epithelial cells and reduce expression of renal injury markers NGAL and Kim-1. The pharmaceutical composition contains GJ103 and a pharmaceutical carrier, the preparation form can be a 4mg / mL injection (the purity is greater than or equal to 99.46%) or an oral preparation, and a new strategy is provided for clinical treatment of cisplatin renal toxicity.

The invention belongs to the technical field of biological medicines, and particularly relates to application of poecilobdella manillensis in preparation of a medicine for treating renal injury. The invention provides a new application of poecilobdella manillensis in preparation of a medicine for treating renal injury, serum biochemical index detection proves that the poecilobdella manillensis can effectively reduce serum creatinine and blood urea nitrogen levels, increase serum albumin and total protein content, remarkably improve glomerular filtration function and protein metabolism function, and improve renal function. And the improvement degree of the traditional Chinese medicine composition is superior to that of a traditional Chinese medicine contrast. Although the curative effect is slightly poorer than that of a chemical drug group, the safety advantage is remarkable. The poecilobdella manillensis can comprehensively regulate renal function metabolism indexes, relieve kidney injury and avoid common side effects of chemical drugs, provides a new choice for clinical treatment of kidney injury, and is especially suitable for chronic kidney disease patients needing long-term treatment.

The invention belongs to the technical field of nano-enzymes, and particularly relates to a preparation method and application of a porous RuO2 nano-enzyme for detecting creatinine. Comprising the following steps: ultrasonically dispersing Ca (NO3) 2.4 H2O, RuCl3 and glycine in deionized water to obtain a mixed solution A; dissolving sodium alginate in deionized water, and uniformly stirring to obtain a mixed solution B; injecting the mixed solution B into the mixed solution A, slowly stirring to form bimetallic hydrogel, washing with deionized water, and freeze-drying to obtain a solid A; calcining the solid A to obtain a solid B; and adding the solid B into hydrochloric acid for ultrasonic dispersion, stirring for a period of time, and centrifugally washing and drying the precipitate in vacuum to obtain the loose and porous RuO2 nano-particles. The nanoparticles prepared by the invention have abundant pore structures and great specific surface area, active sites can be fully exposed, and the POD enzyme activity is remarkably improved.

The invention belongs to the technical field of biological medicines, and particularly discloses a novel application of Epiblastatin A in preparation of a medicine for relieving cisplatin-induced acute kidney injury. The application disclosed by the invention for the first time reveals that by inhibiting the activity of Casein Kinase 1 (CK1) kinase, Epiblastine A can obviously relieve renal dysfunction and kidney tissue structure damage caused by cis-platinum. Experiments prove that the compound can effectively reduce serum creatinine and urea nitrogen levels, significantly improve renal tubule pathological injury, down-regulate expression of renal injury early-stage specific biomarkers KIM-1 and NGAL, and definitely inhibit renal tubule epithelial cell apoptosis in an in-vitro model. The invention also provides a specific pharmaceutical composition containing the Epiblastin A and a preparation form of the specific pharmaceutical composition. The invention provides a brand new mechanism and a high-efficiency and low-toxicity treatment strategy for clinically preventing and treating cisplatin dosage-limited renal toxicity, and has important clinical application value.

The invention discloses a creatinine detection device, and belongs to the field of in-vitro diagnosis equipment. The creatinine detection device comprises a substrate, a reagent 1 assembly and a reagent 2 assembly, the reagent 1 assembly comprises a flow pad, an enzyme pad and a blood filter membrane, the reagent 2 assembly comprises a start inhibition layer, a separation layer and a color development layer, the reagent 1 assembly and the reagent 2 assembly are stored in a non-contact mode in a normal state, and the reagent 1 assembly and the reagent 2 assembly are in contact to start a reaction during testing; the separation layer contains perfluorooctane sulfonic acid and / or perfluorooctane carboxylic acid. According to the creatinine detection device provided by the invention, interference of endogenous ammonia can be eliminated, the diffusivity of the ammonia is improved, and the detection sensitivity is improved.

The invention discloses combined probiotics for improving sarcopenia as well as a preparation method and application of the combined probiotics, and belongs to the field of probiotics. The invention relates to a combined probiotic for improving sarcopenia. The combined probiotic comprises a lactobacillus reuteri body, a lactobacillus johnsonii body, a lactobacillus fermentum body and a bifidobacterium adolescentis body. The combined probiotics disclosed by the invention can be used for remarkably improving the overall symptoms of sarcopenia model mice, including inhibiting weight loss, constipation symptoms and colonic mucosa destruction, prolonging load swimming time, improving muscle endurance, improving skeletal muscle atrophy, improving the expression of I-type slow muscle fiber protein MyHC I and promoting slow muscle fiber repair, and has the effects of preventing and treating sarcopenia. The invention discloses a probiotic intervention method for treating sarcopenia, which comprises the following steps of: preparing probiotics for treating sarcopenia, reducing the content of inflammatory cytokines in muscular tissues, increasing the content of hepatic glycogen, improving systematic metabolism of mice with sarcopenia and damaged serum markers, including lactic acid, lactic dehydrogenase, creatine kinase, creatinine, alanine transaminase ALT and aspartate transaminase AST, providing a new scheme for probiotic intervention for sarcopenia, and being used for preparing related functional products or intervention means.

The application discloses a composition for protecting liver and strengthening kidney and reducing uric acid, which is made of the following raw material components: Anoectochilus roxburghii, dried tangerine or orange peel, chicory, gardenia, turmeric, Hovenia dulcis Thunb, Cistanche deserticola Y.C.Ma, Rehmannia glutinosa, potassium citrate, sodium citrate and goose myo-peptide. The composition combines the immortal concept of TCM (Traditional Chinese Medicine) "treating disease from the root" and the uric acid control method of modern nutritional medicine as an organic whole, and achieves multiple effects of protecting liver and strengthening kidney, mutual benefit of yin and yang and reducing uric acid through multiple action targets. Animal experiment results show that the composition can effectively reduce the activities of transaminase ALT and AST, relieve liver damage, reduce serum creatinine level and improve urea ammonia excretion rate, improve kidney function, inhibit the activities of xanthine oxidase and adenosine dehydrogenase and reduce uric acid level. The composition is safe and has no toxic side effects, is suitable for people with insufficient liver and kidney functions and hyperuricemia and has a wide application prospect.

The invention relates to the technical field of medicines, in particular to application of lycium barbarum-derived extracellular vesicles in preparation of a medicine for treating acute kidney injury. The used extracellular vesicles derived from Chinese wolfberry fruits have a lipid bilayer membrane structure, are good in stability, free of remarkable toxicity, good in blood compatibility and high in-vivo safety after long-term intravenous injection, are used for preparing the medicine for treating the acute kidney injury, and can reduce apoptosis, inhibit rising of blood urea nitrogen and creatinine levels and relieve injury of kidney tissues; the invention further provides application of the extracellular vesicles derived from the Chinese wolfberry fruits in preparation of the medicine for treating the lung injury disease, the weight loss is relieved, lung tissue is protected, meanwhile, the pulmonary alveolar-capillary barrier can be repaired, and in addition, the medicine can be used for treating the lung injury disease. The invention also provides application of the extracellular vesicles derived from Chinese wolfberry fruits in preparation of nuclear transcription factor kappa B inhibitors and / or inhibition of apoptosis and / or repair of pulmonary alveolar capillary barriers.

The invention relates to the technical field of critical index monitoring methods, in particular to an intelligent critical index monitoring method and system based on clinical data. According to the method, a standardized data packet is constructed by collecting vital sign data of a patient, an inspection index group, drug intervention parameters and individual characteristics of the patient; calculating an individualized drug metabolism correction coefficient based on the liver and kidney function state and a real-time creatinine value, and dynamically generating a drug influence factor in combination with the flow rate of an analgesia pump; scene classification is carried out according to the medicine influence factor value and the blood pressure change trend, and the alarm weight of each monitoring index is dynamically adjusted; and finally, accurate risk assessment and graded early warning are realized through multi-index fusion analysis. The system comprises a data acquisition function module, a dynamic analysis function module, a weight adjustment function module and an early warning decision function module. The clinical problem that a traditional monitoring system is insufficient in sensitivity to progressive deterioration in a drug interference environment is effectively solved, and a more reliable safety monitoring scheme is provided for postoperative high-risk patients.

The invention relates to the technical field of medical systems, and particularly discloses a method for constructing a cancer malignant fluid prognosis composite index CCAR based on a creatinine and CAR combination, and the method comprises the following steps: S1, obtaining serum biomarker data of a cancer malignant fluid patient, including creatinine, C-reactive protein and albumin; s2, calculating the ratio CAR of the C reactive protein to the albumin, wherein CAR = CRP / Albumin; s3, taking the CAR and the Cr as input features, and constructing a nonlinear composite index CCAR through a random forest machine learning model; s4, developing a network calculator system; the CCAR index constructed by the invention can comprehensively reflect the inflammation burden, the metabolic state and the immune level of the cancer and malignant fluid patients, and compared with the traditional index, the CCAR index can provide more accurate survival prognosis prediction; creatinine, the ratio of C-reactive protein to albumin and other parameters contained in the CCAR index are all clinical common blood examination items, the obtaining approach is simple and convenient, and wide clinical application is facilitated.

The invention relates to the technical field of clinical decision support and medical data intelligent analysis, in particular to a critical patient individualized liquid resuscitation decision support system, which is characterized in that a data acquisition unit acquires pulse pressure variation waveform and multi-dimensional physiological data of each stroke volume; a volume benefit analysis channel of the dynamic decision-making unit segments a respiratory cycle, extracts pulse pressure fluctuation characteristics, outputs a per-stroke volume increase probability value through a machine learning classifier, an organ injury early warning channel calculates a blood lactic acid and creatinine clearance rate change rate, and generates an acute kidney injury risk sign in combination with inferior vena cava image verification; the execution control unit sends an infusion control or limit instruction according to the combined state; and the feedback optimization unit adjusts the weight of the model according to the actual value of blood lactic acid removal, and recalculates the probability value, so that individualized precise resuscitation, balance capacity benefit and organ protection are realized, and the treatment safety and effectiveness are improved.

The invention provides a traditional Chinese medicine composition for treating nephropathy as well as a preparation method and application thereof, and the anti-renal fibrosis effect is remarkably improved by optimizing a leech extraction process and a novel preparation technology. Animal experiments show that urine protein of model animals can be reduced by 67% and serum creatinine can be reduced by 42% after 12 weeks of continuous administration. Clinical tests prove that the traditional Chinese medicine composition has a definite curative effect on IgA nephropathy, membranous nephropathy and the like, and a new choice is provided for treating chronic kidney diseases.

The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human.

This invention provides a continuous method for preparing high-purity creatine monohydrate, comprising the following steps: a) adding chloroacetic acid aqueous solution dropwise to an aqueous methylamine solution, stirring at room temperature for 2 hours after the addition is complete; b) heating to 50-60°C and holding for 1 hour to remove most of the methylamine, then heating to 95°C to evaporate the methylamine aqueous solution for 1 hour; c) adding sodium hydroxide solution dropwise to the solution from step b) at 95°C, then heating to 105°C and concentrating under reduced pressure for 1.5 hours to approximately half the original volume, obtaining a creatine solution with a concentration of 30%-40%; d) cooling the solution from step c) to 40-60°C and adding a catalyst; e) drying to obtain pure creatine monohydrate. This invention reduces the methylamine equivalent, saving costs, and eliminates the need for purifying creatine for direct use in the next reaction; it can simultaneously lower the system reaction temperature and pH value to inhibit the formation of byproducts dicyandiamide and creatinine, and eliminates the need for debittering agents for purification and debittering, thus saving production costs.

The invention relates to the technical field of data analysis, and particularly discloses a data analysis method and system for acute kidney injury, and the method comprises the steps: integrating the multi-source acute kidney injury data of a patient, including clinical information and historical medical records, constructing the time series data of serum creatinine, urine volume and the like, extracting the risk features in an unstructured text by using an NLP technology, and analyzing the risk features in the unstructured text. Physiological index dynamic and semantic risk factors are deeply fused through space-time alignment, a basic feature vector is formed, a difference risk score of historical and current states is calculated in combination with sliding window features of historical medical records, when the score exceeds a preset threshold value, it is judged that a dynamic evolution risk exists, an advanced intervention instruction is automatically generated, and early intervention is achieved. Therefore, the problems of single data dimension, risk identification lagging and untimely intervention of a traditional method are solved.

The invention belongs to the technical field of reproductive medicine and clinical metabolism intervention, and particularly relates to a group of markers for diagnosing unexplained recurrent abortion and application thereof. Aiming at the clinical pain point that unexplained recurrent abortion (URSA) lacks accurate metabolic typing diagnosis indexes and targeted treatment means, based on detection of a large number of clinical samples and verification of cell experiments, direct association between down-regulation of levels of choline related metabolites and trimethylamine oxide (TMAO) of decidua tissues and the RSA is disclosed for the first time; the core effect of TMAO in-situ synthesis of decidua stromal cells (DSC) in regulation and control of the decidualization process is determined; meanwhile, an RSA indication screening system of joint detection of serum creatinine and decidua choline metabolism is constructed, a targeted TMAO targeted intervention scheme is formed in a matched mode, a diagnosis and treatment closed loop of RSA from precise typing to targeted treatment is achieved, and a brand new technical path is provided for clinically solving the URSA diagnosis and treatment problem.

It suppresses the decrease in creatine content over time. [Solution] The cosmetic composition contains zinc element (A), creatine (B), and creatinine (C).

An application for the EGT-AuNPs in preparing contrast agents and / or antioxidants is provided, where the EGT-AuNPs include gold nanoparticles (AuNPs), the AuNPs are connected to L-ergothioneine (EGT) by gold-sulfur bonds, and the antioxidants include medicines for preventing and / or treating acute kidney injury (AKI). EGT-AuNPs with antioxidant activity are designed and synthesized through the combination of the higher imaging contrast of gold and the antioxidant natural product EGT, and they are ultra-small AuNPs, which achieve the combination of CT imaging and antioxidant effects, and are suitable for renal imaging, particularly for the early diagnosis and treatment of AKI, realizing the integration of diagnosis and treatment, circumventing the toxicity of contrast agents present in the conventional nanomaterials, lowering the serum creatinine and urea nitrogen levels, and reducing the degree of renal tubular damage.

The application relates to an application of a drug for preventing and treating deafness in preparation of a drug for preventing and treating acute kidney injury caused by cisplatin, wherein the effective component of the drug for preventing and treating acute kidney injury caused by cisplatin is prepared from raw medicinal materials in the following weight percentage: 27-33% of ginseng, 16-20% of astragalus, 16-20% of pueraria, 11-13% of curcuma, 12-15% of platycodon, and 8-10% of licorice. The drug for preventing and treating acute kidney injury caused by cisplatin in the application can obviously reduce the creatinine and urea nitrogen levels, improve the morphological damage of kidney tissues, and has a remarkable effect on preventing and treating acute kidney injury caused by cisplatin.

The invention discloses a biomarker, application of the biomarker in predicting the risk of diabetic nephropathy and a kit, which can realize non-invasive efficient evaluation on the severity of diabetic nephropathy and provide important supplement for early diagnosis and refined risk stratification of diabetic nephropathy. The ratio of the Sulfatase-1 to the creatinine Cr is uSULF1 / Cr, and the Sulfatase-1 and the creatinine Cr are both from urine.

Methods of administering an anti-arrhythmic, such as dofetilide, to a patient in an amount effective for treating a cardiovascular condition are described. The drug can be administered intravenously for at least one hour. A loading dose of 0.1 to 12 μg / kg bodyweight over a duration of up to 60 minutes can be administered and / or a maintenance dose of 0.1 to 10 μg / kg / hr can be administered intravenously over a duration of at least 1 hour, optionally alternatively or in addition wherein the amount of the loading dose and / or the IV maintenance dose is in the range of about ±50% of a maintenance dofetilide dose. The cardiovascular condition can include atrial fibrillation or flutter, ventricular tachycardia, hemodynamically stable or unstable ventricular tachycardia, paroxysmal atrial fibrillation, ventricular fibrillation, paroxysmal supraventricular tachycardia, heart failure, coronary artery disease, or pulmonary artery hypertension. A patient's QT interval and / or a creatinine clearance can be measured, and the effective amount can be selected based on either or both of the QT interval or the creatinine clearance measurements.

The invention discloses application of Htr2b and an inhibitor thereof in prevention or treatment of chronic kidney diseases, provides application of Htr2b as a drug target in screening of drugs for prevention or treatment of chronic kidney diseases, and further provides application of the inhibitor of Htr2b in preparation of drugs for prevention or treatment of chronic kidney diseases. It is found that after the Htr2b function of DIO mice is inhibited, kidney injury caused by high fat is obviously relieved, the Htr2b inhibitor can inhibit important inflammatory factors MCP-1, IL-1, IL-6 and TNF-alpha and ectopic lipid deposition of the chronic kidney diseases, renal function markers of creatinine, urea nitrogen and UACR of the DIO mice can be obviously reduced, and the Htr2b inhibitor has the obvious effect of preventing or treating the chronic kidney diseases and has a good application prospect. The compound can be used for preparing medicines for preventing or treating chronic kidney diseases.

The application provides use of zanamivir in preparation of a medicine for treating or preventing preeclampsia, and a corresponding medicine and treatment method; zanamivir can effectively improve high blood pressure, proteinuria, creatinine, neuraminidase and sialic acid elevation symptoms of preeclampsia, increase NO level, and improve pregnancy outcome. Zanamivir and hydroxyprogesterone caproate in combination show better effects.

Provided herein are methods of treating ANCA-associated vasculitis (AAV) in individuals in need thereof comprising administering a complement component 5a receptor (C5aR) antagonist. Also provided herein are methods of treating a ANCA-associated vasculitis (AAV) with renal involvement in an individual in need thereof comprising administering a complement component 5a receptor (C5aR) antagonist to the individual if the individual exhibits an elevated urinary soluble CD163 (sCD163) to creatinine ratio compared to individuals without AAV. In some embodiments, the complement component 5a receptor (C5aR) antagonist is avacopan.

The invention relates to the technical field of medical information systems, in particular to a nursing system for tumor patients in a chemoradiotherapy period, which comprises a physiological monitoring module, a threshold evaluation module, a path switching module, a task decomposition module and a nursing scheduling module. According to the method, by continuously collecting multi-dimensional physiological data such as the heart rate, the blood oxygen saturation degree, the blood pressure and the serum creatinine of the patient and conducting noise suppression processing, stable bearing state information can be obtained, and dynamic quantitative evaluation of the tolerance degree is achieved in combination with deviation analysis of the nursing base line; the nursing task is subjected to priority and rhythm adjustment when the bearing index exceeds the limit, the high-load task is split by utilizing fluctuation prediction, and the interval duration is set, so that the risk caused by physiological burden concentration is reduced, the nursing execution rhythm matched with the real-time state of a patient is formed, and the flexibility of load distribution and the instantaneity of intervention response are realized. And the accuracy and safety of whole-course nursing are improved.

The invention discloses an apigenin derivative, a preparation method and application of the apigenin derivative in uric acid lowering drugs, the apigenin derivative has a molecular structure expression shown in the specification, and research shows that the apigenin derivative can lower uric acid through the dual effects of generation inhibition and excretion promotion, has no obvious influence on 24-hour urine creatinine and is expected to have good kidney safety.

The invention discloses a walnut-derived xanthine oxidase inhibitory peptide and application thereof, and belongs to the technical field of bioactive peptide biology. The amino acid sequence of the xanthine oxidase inhibitory peptide provided by the invention is as shown in SEQ ID No. 1. Through in-vitro activity determination, the IC50 value of the inhibitory peptide is 3.34 mg / mL, and it is proved that the inhibitory peptide has high inhibitory activity on xanthine oxidase. Besides, the inhibitory peptide can reduce the levels of creatinine, urea nitrogen, adenosine deaminase, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, regulate the expression of kidney uric acid resorption protein URAT1, uric acid excretion protein GLUT9 and ABCG2, and significantly reduce the generation of uric acid, can be used for inhibiting xanthine oxidase and preventing or improving hyperuricemia, is applied to preparation of drugs for improving hyperuricemia, and has broad application prospects. The medicine takes the active peptide as the only active ingredient or one of the active ingredients, and has a good application prospect.

The application belongs to the technical field of biological medicine, and particularly relates to a radix morindae officinalis-inulin composition and application thereof in a kidney fibrosis product. The radix morindae officinalis-inulin composition provided by the application is composed of radix morindae officinalis polysaccharide, inulin and water, can exert the synergistic effect of the two polysaccharides, improve the physical and chemical properties and biological activity of the radix morindae officinalis-inulin composition, can significantly enhance the metabolic rate of urea nitrogen creatinine of the kidney, and can significantly reduce the fibrosis positive area, and has a significant effect on the treatment of kidney fibrosis diseases. The raw materials of the composition are based on natural polysaccharides, have good safety and degradability, and meet the high safety requirements of biological materials in the medical field. Compared with the existing single component, the composite design can realize multi-target effect, significantly improve the treatment effect, and has a great market competitive advantage.